CD47 Blockade Improves the Therapeutic Effect of Osimertinib in Non-small Cell Lung Cancer

Investigators explored a rational combination strategy for enhancing the osimertinib efficacy and found that it induced higher CD47 expression, an important anti-phagocytic immune checkpoint, via the NF-κB pathway.